Our Board
Baroness Professor Susan Greenfield, CBE
Baroness Greenfield, Founder and CEO of Neuro-Bio Ltd is a neuroscientist and has published over 200 papers in peer-reviewed journals over the course of her 40-year career, based mainly at Oxford University. She holds 32 honorary degrees from UK and foreign universities, has received numerous honours including the Legion d’Honneur from the French Government, an Honorary Fellowship from the Royal College of Physicians, The American Academy of Achievement Golden Plate Award, and The Australian Medical Research Society Medal. She is also a Fellow of the Royal Society of Edinburgh.
James Phipson
Chairman
James is the Founder and Chief Executive of Dragon Argent (formerly Clink Ltd), which provides integrated legal, financial, HR and other professional services to hundreds of tech startups and SME’s, often internationally. James advises a large number of these high growth, entrepreneurial businesses at board level. Having set up his first successful business at 14 (buying and selling old red telephone kiosks), he is a widely experienced entrepreneur and consummate professional, whose passion, integrity and assistance have always been critical to any organisation with which he has been involved.
Todd Thomson
Todd is an accomplished operating executive and entrepreneur, having served as Citigroup CFO for 5
years and as CEO of Citigroup’s $10 Billion Global Wealth Management division for 2.5 years. Todd is a
leading practitioner on M&A and business strategy, having led the acquisition and strategy efforts for
Citigroup and GE Capital, as well as serving as advisor to Fortune 500 firms while at Bain & Co., Booz
Allen Hamilton, and Barents Group.
At Kairos, Todd oversees all operational and financial aspects of the firm and serves on the Kairos
Investment Committee. Kairos has partnered closely with 16 prominent universities to select and
commercialize their most ground-breaking patented innovations in life sciences and physical sciences.
Todd received his MBA, with Distinction, from the Wharton School of Business and his BA in Economics
from Davidson College.
Stephanie Kawecki
Stephanie is a translational biotechnology scientist with expertise in applied cell biology, tissue engineering, and the development of scalable biological systems. She earned her PhD in Bioengineering from the University of California, Los Angeles (UCLA), where her research focused on mechanistic cellular systems and how microenvironmental signals influence cell behavior and function. Her work has centered on translating laboratory-scale biological insights into scalable applications.
At Kairos Ventures, Stephanie supports and evaluates a diverse portfolio of early-stage companies across the life sciences and physical sciences.
Douglas Anderson
Douglas is an actuary, specialising in longevity data science, and has 40 years’ experience in the financial services sector. He founded and successfully-scaled Club Vita to be an international provider of longevity data analytics to pension funds and life insurers, and he has had a long-term personal interest in dementia research. Douglas is currently studying for a masters in longevity science.
Gianluca Riccio
Gianluca is a distinguished financial leader with over 25 years’ experience across banking, strategy, and risk management at institutions including UBS and Lloyds Banking Group. As a Non-Executive Director at NeuroBio and Chair of its Financial Advisory Board, he provides critical oversight for the company’s financial strategy. Gianluca holds prominent international roles, including Chair of the ‘Business at OECD’ Finance Committee and Co-Chair of the B20 Finance & Infrastructure Taskforce. A prolific thought leader and author, he combines deep technical expertise in data and regulatory needs with a passion for navigating global market complexities to drive organizational transformation.
Watch Professor Herrling contribute to the Press Conference held on the 5th of April 2022 at the Royal College of Physicians